2型糖尿病男性患者糖化血红蛋白水平与骨代谢标志物的相关性*

Correlation between glycosylated hemoglobin level and bone metabolic markers in male patients with type 2 diabetes mellitus*

摘要:

目的?分析2型糖尿病（T2DM）男性患者糖化血红蛋白（HbA1c）水平与骨代谢标志物浓度的相关性。方法?回顾性分析2018年5月—2019年5月在朝阳市第二医院住院治疗的432例T2DM男性患者作为研究对象。根据患者HbA1c水平，将其分为高HbA1c组（HbA1c≥7%）342例和低HbA1c组（HbA1c<7%）90例。收集两组一般资料、血糖相关指标及骨代谢标志物，并观察其差异。使用Pearson法分析HbA1c与 25（OH）D、骨钙素（OCN）、血清总I型胶原氨基端延长肽（TPINP）、I型胶原羧基端肽β特殊序列（β-CTX）骨代谢相关指标的相关性。结果?两组年龄、BMI及病程比较，差异无统计学意义（P?>0.05）。高HbA1c组空腹血糖（FPG）、餐后2?h血糖（2?hFPG）及HbA1c高于低HbA1c组（P?<0.05），而空腹胰岛素（FINS）低于低HbA1c组（P?<0.05）。高HbA1c组OCN低于低HbA1c组（P?<0.05）；两组25（OH）D、TPINP及β-CTX水平比较，差异无统计学意义（P?>0.05）。HbA1c与OCN呈负相关（r?=-0.162，P?=0.002），而与 25（OH）D、TPINP及β-CTX无相关性（P?>0.05）。结论?T2DM男性患者HbA1c水平与OCN呈负相关。

Abstract:

Objective To analyze the correlation between the level of glycosylated hemoglobin (HbA1c) and the concentration of bone metabolic markers in male patients with type 2 diabetes mellitus (T2DM). Methods A total of 432 male patients with T2DM who were hospitalized from May 2018 to May 2019 were retrospectively analyzed. According to the level of HbA1c, the patients were divided into high HbA1c group (HbA1c ≥ 7%) with 342 cases and low HbA1c group (HbA1c < 7%) with 90 cases. Data of general characteristics, blood-sugar-related indicators and bone metabolic markers of two groups of patients were collected, and the differences in these indexes between the two groups were compared. Pearson correlation analysis was used to observe the correlation between HbA1c and 25 (OH) D, osteocalcin (OCN), total procollagen type I intact N-terminal propeptide (TP1NP), and beta-CTX. Results There was no significant difference in age, BMI and course of disease between the two groups (P?>?0.05). The fasting blood glucose (FBG) and 2-hour postprandial blood glucose (2?hPBG) levels in the high HbA1c group were higher than those in the low HbA1c group (P??0.05). HbA1c was negatively correlated with OCN (r?= 0.162, P??0.05). Conclusions There is a negative correlation between glycosylated hemoglobin and osteocalcin in male patients with type 2 diabetes mellitus.